2023 World Conference on Lung Cancer (Posters)-EP10.01. Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression after Treatment with Durvalumab

EP10.01. Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression after Treatment with Durvalumab - PDF(Slides)

Back to course

Pdf Summary

This retrospective study aimed to evaluate treatment options and outcomes for patients with non-small cell lung cancer (NSCLC) who experienced disease progression after receiving durvalumab as consolidation therapy. The PACIFIC trial demonstrated the efficacy of durvalumab compared to placebo in improving overall survival and progression-free survival rates for locally advanced stage III NSCLC.<br /><br />The study included 37 patients who had previously been diagnosed with unresectable stage III NSCLC and had received concurrent chemoradiation followed by durvalumab. Treatment plans after disease progression were recorded, and patients were assessed for any biomarkers that could influence treatment options.<br /><br />Following disease progression, patients received immunotherapy, chemotherapy, targeted therapy, radiation alone, or a combination of these treatments. Outcomes varied, with 41% of patients remaining stable, 13% experiencing disease progression, 27% dying, 8% enrolling in hospice care, and 11% having unknown outcomes. Overall, the incidence of death was low in patients who started treatment after disease progression.<br /><br />The study found that patients treated with immunotherapy alone or in combination with chemotherapy had improved overall survival and second progression-free survival. However, there were discrepancies in the management of patients following treatment for stage III NSCLC, highlighting the need for further research to establish optimized treatment strategies and improve outcomes.<br /><br />The study concluded that while patients treated with immunotherapy showed improved overall survival, there is a critical need for further research to optimize treatment strategies for patients with NSCLC who experience disease progression after receiving durvalumab. The survival data will be further analyzed as it matures.<br /><br />The baseline characteristics of the patients included in the study showed that the majority were between 59-73 years old, with a near equal distribution between males and females. Most patients had adenocarcinoma histology, while the rest had squamous cell carcinoma.

Asset Subtitle

Bushra Shariff

Meta Tag

Speaker Bushra Shariff

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

retrospective study

treatment options

outcomes

NSCLC

durvalumab

PACIFIC trial

overall survival

progression-free survival

immunotherapy

chemotherapy